Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
JOURNALS
PSYCHOPHARMACOLOGY BULLETIN
FULL ISSUE STACKED PDFs
T.E.N.
MENTAL FITNESS
PSI
ONCOLOGY SPECTRUMS
PROJECTS
JOURNAL SUPPLEMENTS
PHYSICIAN ACADEMY SERIES
POCKET REFERENCE GUIDES
TEACHING MONOGRAPHS
MEDWORKS REPRINT SERIES
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
PSYCHIATRIC RATING SCALES
NEWS
Duloxetine for the Treatment of Major Depressive Disorder
1 x
$
30.00
View Cart
Checkout
Home
The Next Step Forward: A Move Toward Evidence, and Away From Fear of the Industry
“Duloxetine for the Treatment of Major Depressive Disorder” has been added to your cart.
View cart
The Next Step Forward: A Move Toward Evidence, and Away From Fear of the Industry
$
0.00
The Next Step Forward: A Move Toward Evidence, and Away From Fear of the Industry quantity
Add to cart
Want a discount? Become a member by purchasing
Psychopharmacology Bulletin Subscription - Individual
!
Categories:
Psychopharmacology Bulletin
,
VOL 36 No. 4 Articles
Tags:
a-move-toward-evidence
,
editors-note
,
industry
,
michael-e-thase
Description
Description
Editor’s Note: The Next Step Forward: A Move Toward Evidence, and Away From Fear of the Industry – Michael E. Thase, MD
Related products
Psychopharmacology Bulletin VOL 36 Supplement No. 3 – Full Issue Stacked PDF
$
60.00
Add to cart
Details
Remission as the Critical Outcome of Depression Treatment
$
30.00
Add to cart
Details
Are SNRIs More Effective than SSRIs? A Review of the Current State of the Controversy
$
30.00
Add to cart
Details
Duloxetine for the Treatment of Major Depressive Disorder
$
30.00
Add to cart
Details
Page load link
Go to Top
